Evidence map›Paper›PMID 36230900›Full record

ReviewCells2022

Functional Repercussions of Hypoxia-Inducible Factor-2α in Idiopathic Pulmonary Fibrosis.

Ana Karen Torres-Soria, Yair Romero, Yalbi I Balderas-Martínez, Rafael Velázquez-Cruz, Luz Maria Torres-Espíndola, Angel Camarena, Edgar Flores-Soto, Héctor Solís-Chagoyán, Víctor Ruiz, Ángeles Carlos-Reyes and 5 more

Open access · goldAbstract readReview
In one paragraph

Review in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 1 country.

Ana Karen Torres-SoriaRed MEDICI, Carrera de Médico Cirujano, Facultad de Estudios Superiores de Iztacala Universidad Nacional Autónoma de México, Mexico City 54090, Mexico.ORCID 0000-0002-1622-4346
Yair RomeroFacultad de Ciencias, Universidad Nacional Autónoma México, Mexico City 04510, Mexico.ORCID 0000-0002-8707-025X
Yalbi I Balderas-MartínezLaboratorio de Biología Computacional, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City 14080, Mexico.ORCID 0000-0001-6400-0526
Rafael Velázquez-CruzLaboratorio de Genómica del Metabolismo Óseo, Instituto Nacional de Medicina Genómica, Mexico City 14610, Mexico.ORCID 0000-0003-4515-0777
Luz Maria Torres-EspíndolaLaboratorio de Farmacología, Instituto Nacional de Pediatría, Mexico City 04530, Mexico.
Angel CamarenaLaboratorio de HLA, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City 04530, Mexico.
Edgar Flores-SotoDepartamento de Farmacología, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico.ORCID 0000-0003-2649-8751
Héctor Solís-ChagoyánSubdirección de Investigaciones Clínicas, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico City 14370, Mexico.ORCID 0000-0003-0692-6931
Víctor RuizDepartamento de Fibrosis Pulmonar, Laboratorio de Biología Molecular, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City 14080, Mexico.ORCID 0000-0003-0440-2093
Ángeles Carlos-ReyesLaboratorio de Onco-Inmunobiología, Departamento de Enfermedades Crónico-Degenerativas, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City 14080, Mexico.
Citlaltepetl Salinas-LaraRed MEDICI, Carrera de Médico Cirujano, Facultad de Estudios Superiores de Iztacala Universidad Nacional Autónoma de México, Mexico City 54090, Mexico.
Erika Rubí Luis-GarcíaDepartamento de Fibrosis Pulmonar, Laboratorio de Biología Celular, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City 14080, Mexico.ORCID 0000-0003-3829-0536
Jaime ChávezDepartamento de Hiperreactividad Bronquial, Instituto Nacional de Enfermedades, Respiratorias Ismael Cosío Villegas, Mexico City 14080, Mexico.ORCID 0000-0001-7472-2936
Manuel Castillejos-LópezDepartamento de Epidemiología y Estadística, Instituto Nacional de Enfermedades, Respiratorias Ismael Cosío Villegas, Mexico City 14080, Mexico.ORCID 0000-0001-8689-9755
Arnoldo Aquino-GálvezDepartamento de Fibrosis Pulmonar, Laboratorio de Biología Molecular, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City 14080, Mexico.
Instituto Nacional de Enfermedades Respiratorias · MXUniversidad Nacional Autónoma de México · MXInstituto Nacional de Pediatria · MXInstituto Nacional de Psiquiatría Ramón de la Fuente Muñiz · MXNational Institute of Genomic Medicine · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypoxia and hypoxia-inducible factors (HIFs) are essential in regulating several cellular processes, such as survival, differentiation, and the cell cycle; this adaptation is orchestrated in a complex way. In this review, we focused on the impact of hypoxia in the physiopathology of idiopathic pulmonary fibrosis (IPF) related to lung development, regeneration, and repair. There is robust evidence that the responses of HIF-1α and -2α differ; HIF-1α participates mainly in the acute phase of the response to hypoxia, and HIF-2α in the chronic phase. The analysis of their structure and of different studies showed a high specificity according to the tissue and the process involved. We propose that hypoxia-inducible transcription factor 2a (HIF-2α) is part of the persistent aberrant regeneration associated with developing IPF.

Indexed as

Basic Helix-Loop-Helix ProteinsIdiopathic Pulmonary FibrosisCell DifferentiationCell HypoxiaHumansHypoxiaBasic Helix-Loop-Helix ProteinsHIFshypoxiaIPFlung regeneration

Identifiers

PMID36230900
PMCPMC9562026
OpenAlexW4296466871

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.